News from eisai A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

21 Nov, 2018, 07:00 GMT New Pan-European Report Highlights Current Isolation Felt by Advanced Breast Cancer Patients

FurtherMore: campaign launched with patient groups across Europe calls for more support tailored to the specific needs of people with advanced breast ...


12 Dec, 2017, 15:41 GMT New European real-world audit data provides additional information on the effectiveness of Zebinix® (eslicarbazepine acetate) for the treatment of partial-onset epilepsy in adults

Results from the pooled analysis presented at the American Epilepsy Society Annual Meeting 2017 in Washington DC, US.[1],[2],[3] Bial and Eisai have...


08 Dec, 2017, 17:37 GMT Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS

Eisai today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (Halaven®), in combination with the Merck & Co....


30 Nov, 2017, 16:37 GMT Halaven® (Eribulin) Remains Available for Patients with Advanced Metastatic Breast Cancer Who Have Progressed After at Least Two Chemotherapeutic Regimens Despite Recent NICE Draft Guidance in an Earlier Setting

The availability of Halaven® (eribulin) for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at...


09 Sep, 2017, 18:23 BST Combination Data for Lenvatinib and Pembrolizumab Demonstrate Notable Response Rates for Patients with Advanced Renal Cell Carcinoma

FOR EMEA MEDICAL MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTS Updated results of advanced RCC cohort from Study 111 support continued...


05 Sep, 2017, 12:00 BST Real-world data confirms clinical effectiveness of Zebinix® (eslicarbazepine acetate) for the treatment of partial-onset epilepsy in Adults

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTS Eslicarbazepine acetate data shows seizure freedom in 41.3% of patients at 12 months, and...


04 Sep, 2017, 12:11 BST Eisai to present new data for lenvatinib in hepatocellular carcinoma and renal cell carcinoma at ESMO 2017 Congress

FOR EMEA MEDICAL MEDIA ONLY: NOT FOR AUSTRIAN/SWISS MEDIA Health-related quality of life analysis of Phase III data for lenvatinib vs sorafenib in...


26 Jul, 2017, 10:45 BST Eisai Submits Marketing Authorisation Application to the European Medicines Agency for Lenvatinib in First-Line Hepatocellular Carcinoma

Lenvatinib filing based on pivotal Phase III REFLECT study demonstrating non-inferior overall survival compared to sorafenib Simultaneous submissions ...


23 Jun, 2017, 09:49 BST Zebinix® (eslicarbazepine acetate) Data Demonstrate No Significant Negative Consequences on Neurocognitive Function in Children with Focal Epilepsy

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTS Eslicarbazepine acetate was shown not to have a significant negative consequence on...


04 Jun, 2017, 14:30 BST New Data Demonstrate Results for Lenvatinib vs. Sorafenib in First-Line Liver Cancer Trial

Lenvatinib is the first systemic therapy to demonstrate non-inferiority to the current standard of care in the primary efficacy endpoint of overall...


30 May, 2017, 00:01 BST Eisai and Charles River Laboratories Announce Extension of Integrated Drug Discovery Partnership

Companies to continue collaboration in discovery of next generation anti-malaria drugs Eisai Co., Ltd. (TYO: 4523), a leading global research and...


23 May, 2017, 00:01 BST European Commission Grants Marketing Authorisation for Zebinix® (eslicarbazepine acetate) as Once-daily Monotherapy in Adults with Newly Diagnosed Partial-onset Epilepsy

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTS Bial and Eisai today announce that the European Medicines Agency (EMA) has approved Zebinix® ...


28 Mar, 2017, 00:01 BST Zebinix® (eslicarbazepine acetate) Receives Positive CHMP Opinion as Once-daily Monotherapy for Newly Diagnosed Focal-onset Epilepsy

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTS Efficacy and safety/tolerability of once-daily eslicarbazepine acetate in the monotherapy...


27 Mar, 2017, 13:32 BST German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx® (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma (RCC)

FOR EMEA HEALTHCARE AND MEDICAL MEDIA ONLY: NOT FOR SWISS/AUSTRIAN JOURNALISTS The decision recognises the convincing clinical benefit lenvatinib...


10 Mar, 2017, 07:01 GMT First-in-class Fycompa® (perampanel) Approved in South Africa for Partial-Onset Seizures

Partnership with Clinigen to provide perampanel in the region Eisai is pleased to announce that perampanel has been approved in South Africa for the...


28 Feb, 2017, 00:01 GMT Halaven® (eribulin) Launches in South Africa for the Treatment of Women with Advanced Breast Cancer

FOR EMEA MEDIA ONLY: NOT FOR SWISS/AUSTRIAN MEDIA Eisai and Clinigen enter partnership to provide eribulin in South Africa for women with advanced...


04 Jan, 2017, 23:01 GMT German Institute for Quality and Efficiency in Health Care (IQWiG) Confirms Additional Benefit for Kisplyx® (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma

FOR EU MEDIA ONLY: NOT FOR SWISS/AUSTRIAN MEDIA Approximately 15,000 people in Germany develop renal cell carcinoma every year.[1] The German...


04 Jan, 2017, 00:01 GMT First-in-class Epilepsy Treatment Fycompa® (perampanel) Launches in Jordan, Kingdom of Saudi Arabia and the United Arab Emirates

Fycompa® (perampanel) is now licensed for adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in Jordan, ...


19 Dec, 2016, 00:01 GMT European Commission Grants Marketing Authorisation for Zebinix® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTS The European Commission extended the Marketing Authorisation for Zebinix® (eslicarbazepine...


12 Dec, 2016, 00:01 GMT New Interim Phase Ib/II Combination Data Investigate Halaven® (eribulin) With Immunotherapy pembrolizumab in Advanced or Metastatic Triple Negative Breast Cancer

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN/US JOURNALISTS New interim data presented today at the San Antonio Breast Cancer Symposium (SABCS),...


05 Dec, 2016, 18:01 GMT Results Presented for Pivotal Phase III Clinical Trial of Adjunctive Rufinamide in Children With Inadequately Controlled Lennox-Gastaut Syndrome

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN/US JOURNALISTS Final data to be presented for the first time at American Epilepsy Society in Houston,...


04 Dec, 2016, 23:01 GMT Considerable Additional Benefit of Eisai's Halaven® (eribulin) in Advanced Liposarcoma Confirmed by the German Federal Joint Committee (G-BA)

FOR EMEA MEDIA ONLY: NOT FOR SWISS/AUSTRIAN JOURNALISTS Eribulin has shown unprecedented survival benefit in advanced liposarcoma in pivotal phase...


04 Dec, 2016, 18:01 GMT New Data for Once-daily Adjunctive Zebinix® (eslicarbazepine acetate) Show Good Seizure Control and Tolerability in People With Partial Onset (Focal) Seizures

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN/US JOURNALISTS Zebinix® (eslicarbazepine acetate) provides a high retention rate, reduction in seizure...


01 Dec, 2016, 00:01 GMT Halaven® (eribulin) Receives Registration in South Africa for Treatment of Women With Advanced Breast Cancer

FOR EMEA MEDIA ONLY: NOT FOR SWISS/AUSTRIAN MEDIA Collaboration between Eisai and Clinigen provides women in South Africa with access to eribulin for ...


29 Nov, 2016, 00:01 GMT New Data for Halaven® (eribulin) at SABCS 2016 Demonstrate Continued Potential in Treatment of Multiple Types of Locally Advanced or Metastatic Breast Cancer

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN/US JOURNALISTS Eisai highlights 17 new data abstracts for eribulin in metastatic breast cancer at the...